References

1.

LUCENTIS [package insert]. South San Francisco, CA: Genentech, Inc; 2017.

2.

Rosenfeld PJ, et al; MARINA Study Group. N Engl J Med. 2006;355:1419-1431.

3.

Brown DM, et al; ANCHOR Study Group. Ophthalmology. 2009;116:57-65.

4.

Regillo CD, et al; PIER Study Group. Am J Ophthalmol. 2008;145:239-248.

5.

Busbee BG, et al; HARBOR Study Group. Ophthalmology. 2013;120:1046-1056.

6.

Campochiaro PA, et al; BRAVO Investigators. Ophthalmology. 2010;117:1102-1112.

7.

Brown DM, et al; CRUISE Investigators. Ophthalmology. 2010;117:1124-1133.

8.

Nguyen QD, et al; RISE and RIDE Research Group. Ophthalmology. 2012;119:789-801.

9.

Data on file. Genentech, Inc. South San Francisco, CA. 

10.

Ho AC, et al; HARBOR Study Group. Ophthalmology. 2014;121:2181-2192.

11.

Brown DM, et al; RISE and RIDE Research Group. Ophthalmology. 2013;120:2013-2022.

12.

Ip MS, et al. Arch Ophthalmol. 2012;130:1145-1152.

13.

Genentech [press release]. South San Francisco, CA: Genentech, Inc. http://www.gene.com/media/press-releases/14661/2017-04-17/fda-approves-genentechs-lucentis-ranibiz. Accessed April 19, 2017.

14.

Gross JG, et al; Writing Committee for the Diabetic Retinopathy Clinical Research Network. JAMA. 2015;314:2137-2146.

15.

American Academy of Ophthalmology. International clinical diabetic retinopathy disease severity scale detailed table. October 2002. http://www.icoph.org/dynamic/attachments/resources/diabetic-retinopathy-detail.pdf. Accessed April 26, 2017.

16.

Early Treatment Diabetic Retinopathy Study Research Group. Ophthalmology. 1991;98:823-833.

17.

American Academy of Ophthalmology Retina/Vitreous Panel. Preferred Practice Pattern® Guidelines. Diabetic Retinopathy. San Francisco, CA: American Academy of Ophthalmology; 2014. Available at: www.aao.org/ppp.

18.

Diabetic Retinopathy Study Research Group. Int Ophthalmol Clin. 1987;27:239-253.